U.S. Markets open in 1 hr 10 mins

Aeolus Pharmaceuticals, Inc. (AOLS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0725+0.0040 (+5.8394%)
At close: 3:56PM EDT
People also watch
AMARCCELPPMDMCETBMSN
Full screen
Previous Close0.0685
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume34,559
Market Cap11.03M
Beta1.62
PE Ratio (TTM)-2.42
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Aeolus Pharmaceuticals, Inc. :AOLS-US: Earnings Analysis: Q1, 2017 By the Numbers : March 20, 2017
    Capital Cube6 months ago

    Aeolus Pharmaceuticals, Inc. :AOLS-US: Earnings Analysis: Q1, 2017 By the Numbers : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis Aeolus Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Aeolus Pharmaceuticals, Inc. – Cleveland BioLabs, Inc., Amgen Inc., Fate Therapeutics, Inc., Albany Molecular Research, Inc., CytRx Corporation, Catalyst Biosciences, Inc. and Ionis Pharmaceuticals, Inc. (CBLI-US, AMGN-US, FATE-US, ... Read more (Read more...)

  • Aeolus Pharmaceuticals, Inc. :AOLS-US: Earnings Analysis: Q4, 2016 By the Numbers : January 5, 2017
    Capital Cube8 months ago

    Aeolus Pharmaceuticals, Inc. :AOLS-US: Earnings Analysis: Q4, 2016 By the Numbers : January 5, 2017

    Categories: Yahoo Finance Get free summary analysis Aeolus Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2016. Highlights Summary numbers: Revenues of USD 0.55 million, Net Earnings of USD -1.02 million. Change in operating cash flow of 54.54% compared to same period last year is about the same as change in earnings, likely no significant ... Read more (Read more...)

  • We're sorry this is all we were able to find about this topic.